Dr. Scott M. Friedman, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 421
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME57010
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Lakeland Regional Medical Center Lakeland, FL
Medical groups
- Gregory L Henderson MD Facs Inc (30 clinicians)
- New Tampa Eye Institute LLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 421
- Services billed
- 228,872
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 29,520 | 95 |
| Injection, ranibizumab, 0.1 mg | 1,001 | 38 |
| Injection of drug into eye | 841 | 145 |
| Imaging of retina | 797 | 350 |
| Established patient complete exam of visual system | 628 | 251 |
| Extended exam of the back part of the eye with retinal drawing | 482 | 282 |
| Established patient office or other outpatient visit, 20-29 minutes | 241 | 174 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 172 | 162 |
| Photography of the retina | 161 | 152 |
| New patient complete exam of visual system | 99 | 99 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Lakeland, FL | 186 |
| Ciprofloxacin Hcl Other prescribers in Lakeland, FL | 106 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Lakeland, FL | 50 |
| Timolol Maleate Other prescribers in Lakeland, FL | 27 |
| Latanoprost Other prescribers in Lakeland, FL | 24 |
| Brimonidine Tartrate Other prescribers in Lakeland, FL | 18 |
| Diclofenac Sodium Other prescribers in Lakeland, FL | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 37 payments worth $4,802 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $2,457 |
|---|---|
| Ocular Therapeutix, Inc. | $800 |
| Regeneron Healthcare Solutions, Inc. | $260 |
| Ani Pharmaceuticals, Inc. | $164 |
| Sight Sciences, Inc. | $149 |
| Regeneron Pharmaceuticals, Inc. | $143 |
| Johnson & Johnson Surgical Vision, Inc. | $129 |
| Dompe US, Inc. | $121 |
| Travel and Lodging | $2,080 |
|---|---|
| Food and Beverage | $1,922 |
| Consulting Fee | $800 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Apellis Pharmaceuticals, Inc. Nov 12, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $1,588 |
| Ocular Therapeutix, Inc. Mar 27, 2025 | Consulting Fee | $800 |
| Apellis Pharmaceuticals, Inc. Nov 12, 2025 | Travel and Lodging travel to Houston, TX · in-kind | $492 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $609,307 in research payments for these studies, mostly to the institutions running them.
- CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
Boehringer Ingelheim International GmbH - A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.